Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor

Choroidal Neovascularization Clinical Trial

Official title:

Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03793400
• Other study ID #: 180916
• Status: Completed
• Start date: March 13, 2018
• Est. completion date: December 28, 2018

Study information

• Verified date: January 2019
• Source: Changhua Christian Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To evaluate the long-term outcome of active choroidal neovascularization (CNV) in punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) after anti-vascular endothelial factor treatment.

Description:

To evaluate the long-term outcome of active choroidal neovascularization (CNV) in punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) after anti-vascular endothelial factor treatment.

The age, sex, best corrected visual acuity (BCVA) in Snellen chart, and refractive status for each patient were recorded. All patients had thorough clinical examinations, including slit lamp biomicroscopy, indirect ophthalmoloscopy, and spectral domain optical coherence tomography during each visit. Fundus photography, fluorescein angiography, and indocyanine angiography were performed on all patients. OCT angiography was performed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: December 28, 2018
• Est. primary completion date: April 13, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Patients were punctate inner choroidopathy or multifocal choroiditis with active choroidal neovascularization.

2. Follow up over 4 years.

Exclusion Criteria:

1. Patients were not punctate inner choroidopathy or multifocal choroiditis with active choroidal neovascularization

2. Patients were punctate inner choroidopathy or multifocal choroiditis with active choroidal neovascularization but loss follow over 1 year.

Related Conditions & MeSH terms

• Choroidal Neovascularization
• Choroiditis
• Neovascularization, Pathologic
• Punctate Inner Choroidopathy

Intervention

Drug:
• Bevacizumab Injection
Anti-vascular endothelial growth factor (VEGF)

Locations

Country	Name	City	State
Taiwan	Changhua Christian Hospital	Changhua

Sponsors (1)

Lead Sponsor	Collaborator
Changhua Christian Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Wilcoxon Signed-Rank test	A statistical comparison of average of two dependent samples	Baseline,48 month.
Secondary	visual acuity	visual acuity in logMAR	Baseline,48 month.